538 related articles for article (PubMed ID: 37359737)
21. Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.
Hillerdal V; Essand M
BioDrugs; 2015 Apr; 29(2):75-89. PubMed ID: 25859858
[TBL] [Abstract][Full Text] [Related]
22. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
[TBL] [Abstract][Full Text] [Related]
23. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.
Bhatia V; Kamat NV; Pariva TE; Wu LT; Tsao A; Sasaki K; Sun H; Javier G; Nutt S; Coleman I; Hitchcock L; Zhang A; Rudoy D; Gulati R; Patel RA; Roudier MP; True LD; Srivastava S; Morrissey CM; Haffner MC; Nelson PS; Priceman SJ; Ishihara J; Lee JK
Nat Commun; 2023 Apr; 14(1):2041. PubMed ID: 37041154
[TBL] [Abstract][Full Text] [Related]
24. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
25. The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer.
Deegen P; Thomas O; Nolan-Stevaux O; Li S; Wahl J; Bogner P; Aeffner F; Friedrich M; Liao MZ; Matthes K; Rau D; Rattel B; Raum T; Kufer P; Coxon A; Bailis JM
Clin Cancer Res; 2021 May; 27(10):2928-2937. PubMed ID: 33504551
[TBL] [Abstract][Full Text] [Related]
26. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Sun BL
Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
[TBL] [Abstract][Full Text] [Related]
28. Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells.
Yazdanifar M; Zhou R; Mukherjee P
Curr Trends Immunol; 2016; 17():95-115. PubMed ID: 28659689
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer.
Bansal D; Reimers MA; Knoche EM; Pachynski RK
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33477569
[TBL] [Abstract][Full Text] [Related]
30. Recent advances of bispecific antibodies in solid tumors.
Yu S; Li A; Liu Q; Yuan X; Xu H; Jiao D; Pestell RG; Han X; Wu K
J Hematol Oncol; 2017 Sep; 10(1):155. PubMed ID: 28931402
[TBL] [Abstract][Full Text] [Related]
31. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial.
Dorff TB; Blanchard MS; Adkins LN; Luebbert L; Leggett N; Shishido SN; Macias A; Del Real MM; Dhapola G; Egelston C; Murad JP; Rosa R; Paul J; Chaudhry A; Martirosyan H; Gerdts E; Wagner JR; Stiller T; Tilakawardane D; Pal S; Martinez C; Reiter RE; Budde LE; D'Apuzzo M; Kuhn P; Pachter L; Forman SJ; Priceman SJ
Nat Med; 2024 Jun; 30(6):1636-1644. PubMed ID: 38867077
[TBL] [Abstract][Full Text] [Related]
32. Emerging Immunotherapy Approaches for Treating Prostate Cancer.
Meng L; Yang Y; Mortazavi A; Zhang J
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762648
[TBL] [Abstract][Full Text] [Related]
33. Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.
Strohl WR; Naso M
Antibodies (Basel); 2019 Jul; 8(3):. PubMed ID: 31544847
[TBL] [Abstract][Full Text] [Related]
34. Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies.
Labriola MK; Atiq S; Hirshman N; Bitting RL
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):301-309. PubMed ID: 33168966
[TBL] [Abstract][Full Text] [Related]
35. Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform.
Borrok MJ; Li Y; Harvilla PB; Vellalore Maruthachalam B; Tamot N; Prokopowitz C; Chen J; Venkataramani S; Grewal IS; Ganesan R; Singh S
Cancer Res Commun; 2022 Mar; 2(3):146-157. PubMed ID: 36874404
[TBL] [Abstract][Full Text] [Related]
36. T cell-engaging therapies - BiTEs and beyond.
Goebeler ME; Bargou RC
Nat Rev Clin Oncol; 2020 Jul; 17(7):418-434. PubMed ID: 32242094
[TBL] [Abstract][Full Text] [Related]
37. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Sadaghiani MS; Sheikhbahaei S; Werner RA; Pienta KJ; Pomper MG; Solnes LB; Gorin MA; Wang NY; Rowe SP
Eur Urol; 2021 Jul; 80(1):82-94. PubMed ID: 33840558
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions.
López-Campos F; Gajate P; Romero-Laorden N; Zafra-Martín J; Juan M; Hernando Polo S; Conde Moreno A; Couñago F
Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327339
[TBL] [Abstract][Full Text] [Related]
39. Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy.
Penny HL; Hainline K; Theoharis N; Wu B; Brandl C; Webhofer C; McComb M; Wittemer-Rump S; Koca G; Stienen S; Bargou RC; Hummel HD; Loidl W; Grüllich C; Eggert T; Tran B; Mytych DT
Front Immunol; 2023; 14():1261070. PubMed ID: 37942314
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy in prostate cancer: current state and future perspectives.
Handa S; Hans B; Goel S; Bashorun HO; Dovey Z; Tewari A
Ther Adv Urol; 2020; 12():1756287220951404. PubMed ID: 32952615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
